BioMarin Pharmaceutical Inc.

BioMarin is a multinational biopharmaceutical company that specializes in providing first-to-market therapeutics to patients with rare genetic diseases. The company's product portfolio comprises three approved products and multiple clinical and preclinical product candidates. Approved products include Naglazyme for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin; Aldurazyme for mucopolysaccharidosis I (MPS I), a product which BioMarin developed through a 50/50 joint venture with Genzyme Corporation; and Kuvan Tablets, a product for the treatment of phenylketonuria (PKU), developed in partnership with Merck Serono, a division of Merck KGaA of Darmstadt, Germany. The company was established in 1997 and employs a staff of 675 worldwide.